DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

about

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

Item

http://www.wikidata.org/entity/Q48533220

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

@en

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

@nl

type

Item

label

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

@en

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

@nl

prefLabel

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

@en

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

@nl

P1476

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy

@en

P2093

Jianguo Hu

http://www.w3.org/2001/XMLSchema#string

Jiao Xu

http://www.w3.org/2001/XMLSchema#string

Lina Hu

http://www.w3.org/2001/XMLSchema#string

Min Yong

http://www.w3.org/2001/XMLSchema#string

Shuaibin Liu

http://www.w3.org/2001/XMLSchema#string

Si Tian

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of macroautophagy triggers apoptosis

Mechanisms of angiogenesis

Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8

A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles.

Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth.

Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma

The incidence of cancer in schizophrenic patients.

Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Role of autophagy in cancer: management of metabolic stress.

Thioridazine inhibits angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR pathway in ovarian cancer xenografts

P304

8171-8177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2017.7184

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

T Yu

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29344260

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5755240

http://www.w3.org/2001/XMLSchema#string